Read our latest updates & insights

On 8 July 2026, Teva and Samsung Bioepis announced that they have entered an agreement for the commercialisation in Canada of Opuviz®/SB15 (aflibercept), biosimilar to Regeneron/Bayer’s Eylea®.  Under the terms of the licence and commercialisation agreement, Samsung Bioepis...

On 7 July 2026, Celltrion announced that it has successfully secured formulary listings for Vegzelma™, biosimilar to Roche/Genentech’s Avastin® (bevacizumab), with two major pharmacy benefit managers (PBMs) in the US.

Vegzelma™ was listed as a preferred drug on the g...

On 6 July 2026, Novartis and Myricx Bio announced that they have entered into an agreement for the acquisition of Myricx Bio by Novartis.  Myricx Bio is a UK-based biotechnology company developing antibody-drug conjugates (ADCs) using N-myristoyltransferase inhibitor (NMTi)...

On 6 July 2026, Seoul Economic Daily reported that Celltrion has filed with the FDA an amendment to its global Phase 3 clinical trial plan for CT-P51, biosimilar to MSD’s Keytruda® (pembrolizumab).  The amendment reduces the number of trial participants from about 600 to ar...

On 2 July 2026, Singaporean-headquartered Prestige Biopharma announced that it had signed a memorandum of understanding (MOU) with US-based Charles River Laboratories to collaborate on biopharmaceutical development, testing and manufacturing.

The collaboration will c...

On 1 July 2026, The Korea Biomedical Review reported that Samsung Epis Holdings has opened and commenced operating its new research and development centre in Beijing.  The establishment of the new R&D centre was first announced by Samsung Epis on 29 May 2026.

The...

On 1 July 2026, Australia’s Pharmaceutical Benefits Scheme published its Summary of Changes, which includes a newly PBS-listed ustekinumab biosimilar and new or expanded PBS-listings for a number of biopharmaceuticals.

The newly PBS-listed ustekinumab biosimilar is A...